Torrance Memorial Physician Network / Cancer Care
Welcome,         Profile    Billing    Logout  
 15 Trials 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chan, David
REACH, NCT03956368: Efficacy of Atorvastatin in Chronic Subdural Haematoma

Recruiting
3
690
RoW
Atorvastatin 20mg, Placebos
Chinese University of Hong Kong
Chronic Subdural Hematoma
09/22
03/23
ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed
3
300
Europe, Canada, US, RoW
89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)
Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd
Clear Cell Renal Cell Carcinoma
10/22
11/22
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT04438304: A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Active, not recruiting
2
63
RoW
64Cu-SARTATE, 64Cu-MeCOSar-Octreotate
Clarity Pharmaceuticals Ltd
Neuroendocrine Tumors
10/24
10/24
NCT04798781: Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

Active, not recruiting
2
16
US
Telatinib, Keytruda, pembrolizumab
Andrew Hendifar, MD, EOC Pharma
Gastric Cancer, Hepatocellular Carcinoma
02/24
02/25
NCT06445114: Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Not yet recruiting
2
50
US
Cisplatin, Chemoradiation
Zachary Zumsteg
Oropharyngeal Cancer, Carcinoma
03/32
03/32
TRIO-US B-12 TALENT, NCT04553770: Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Checkmark Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Recruiting
2
88
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, WHO 10516
Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Daiichi Sankyo Co., Ltd.
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
09/25
09/25
NCT06123286: Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

Not yet recruiting
1
30
US
Tart Cherry, Omega 3 FA (Fish Oil)
Philip Chang, The Cherry Marketing Institute
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
01/27
01/27
PMCH, NCT03615053: Personalized Medicine for Canadians With Hemophilia

Recruiting
N/A
600
Canada
Implementation of WAPPS-Hemo personalized dosing regimen
McMaster University
Hemophilia A, Hemophilia B
09/22
09/23
NCT05143216: High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study

Recruiting
N/A
23
RoW
Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Canula), High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)
Dr. David Yuen Chung CHAN
Chronic Subdural Hematoma
12/22
12/23
HOPE, NCT04725851: High Concentration Oxygen for Pneumocephalus After Evacuation of Chronic Subdural Haematoma

Recruiting
N/A
36
RoW
High concentration Oxygen therapy, Control: Room Air or Low concentration Oxygen
Chinese University of Hong Kong
Chronic Subdural Hematoma, Recurrence, Oxycephaly
12/23
12/24
NCT04403802: Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy

Completed
N/A
28
US
Voxx Human Performance Technology Socks, Placebo Socks
Arash Asher, MD, VoxxLife
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy, Neuropathy
05/24
05/24
ACTRN12618001819213: A novel PET (positron emission tomography) tracer for donut-like PET findings in patients with neuroendocrine tumours

Recruiting
N/A
10
 
Northern Sydney Local Health District, Sydney Vital
Neuroendocrine tumours
 
 
Phan, Vu TN
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
HLX10-020-SCLC302, NCT05353257 / 2022-002226-27: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active, not recruiting
3
511
Europe, US, RoW
HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.
Limited-Stage Small Cell Lung Cancer
07/25
12/26
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
TRIO-US B-12 TALENT, NCT04553770: Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Checkmark Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Recruiting
2
88
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, WHO 10516
Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Daiichi Sankyo Co., Ltd.
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
09/25
09/25
LTRN184-1AST23-1, NCT05933265: Study of LP-184 in Patients with Advanced Solid Tumors

Recruiting
1/2
175
US
LP-184, Spironolactone
Lantern Pharma Inc.
Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
02/25
09/25
EXCLAIM, NCT02716116 / 2016-001271-68: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Checkmark Approved Exkivity in Korea for treatment of 2L NSCLC with EGFR EXON 20 insertion
Jul 2022 - Jul 2022: Approved Exkivity in Korea for treatment of 2L NSCLC with EGFR EXON 20 insertion
Checkmark Conditional marketing authorization received in Great Britain as a monotherapy 2L EGFR Exon20ins+ locally adv NSCLC
Mar 2022 - Mar 2022: Conditional marketing authorization received in Great Britain as a monotherapy 2L EGFR Exon20ins+ locally adv NSCLC
Checkmark Approved Marketing Authorisation Application in China for NSCLC
More
Active, not recruiting
1/2
334
Europe, Japan, US, RoW
TAK-788, AP32788
Takeda
Carcinoma, Non-Small-Cell Lung
03/25
03/25
NCT06132503: Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

Recruiting
1
110
US
LP-284
Lantern Pharma Inc.
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
11/28
11/28
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
02/28
VAC, NCT05969886: Ventricular-Arterial Coupling: A Predictor of Post-Induction Hypotension

Completed
N/A
405
RoW
University Medical Center Ho Chi Minh City (UMC)
Hypotension on Induction
11/24
12/24
Hool, Hugo
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT04798781: Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

Active, not recruiting
2
16
US
Telatinib, Keytruda, pembrolizumab
Andrew Hendifar, MD, EOC Pharma
Gastric Cancer, Hepatocellular Carcinoma
02/24
02/25
NCT06445114: Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Not yet recruiting
2
50
US
Cisplatin, Chemoradiation
Zachary Zumsteg
Oropharyngeal Cancer, Carcinoma
03/32
03/32
UCT01097-001, NCT04761601: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Terminated
1
32
US
UCT-01-097, Gemcitabine, Gemzar, Paclitaxel, Abraxane
1200 Pharma, LLC
Advanced Solid Tumor
02/24
02/24
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Active, not recruiting
1
70
US, RoW
TORL-2-307-MAB
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
12/24
12/25
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Recruiting
1
70
US, RoW
TORL-2-307-ADC
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
01/25
01/26
NCT06123286: Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

Not yet recruiting
1
30
US
Tart Cherry, Omega 3 FA (Fish Oil)
Philip Chang, The Cherry Marketing Institute
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
01/27
01/27
NCT04403802: Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy

Completed
N/A
28
US
Voxx Human Performance Technology Socks, Placebo Socks
Arash Asher, MD, VoxxLife
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy, Neuropathy
05/24
05/24
MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting
N/A
750
Canada, US
MRD
Exact Sciences Corporation, NSABP Foundation Inc
Colorectal Cancer
02/28
02/28

Download Options